|
SEATTLE, WASH., Jan. 4, 2001 — Cell Therapeutics Inc. (cti)
(Nasdaq: CTIC) has previewed the Company's 2001 milestones in a conference
call hosted by CIBC World Markets Corporation.
"The real potential for cti this year is not only the prospect of
growing significant revenues from TRISENOX(TM) sales and its extension
to other larger disease indications, but also from the excitement
stemming from our PG-TXL(TM) product and its application in multiple
phase II trials," said James A. Bianco, M.D., President and CEO. "With
the quarterly newsflow from clinical trials, cancer society meetings,
and publications, this could be a breakout year for the company."
TRISENOX INJECTIONThe company is initiating twelve clinical studies with TRISENOX in a variety of cancers, including multiple myeloma, myelodysplastic syndrome, and front line therapy for acute promyelocytic leukemia (APL). Trials are also planned in chronic myeloid leukemia.
Preliminary preclinical and clinical results in these trials, as well as the ongoing 15 trials sponsored by the National Cancer Institute, are expected to be presented at the following meetings: both the International Myeloma Workshop and American Society of Clinical Oncology (ASCO) meetings in May, an international investigators' meeting in June, The Joint International Conference on APL and Differentiation Therapy in October, and the American Society of Hematology (ASH) in December. A number of key peer reviewed publications are expected quarterly, beginning in the second quarter. Lastly, the Company expects European approval for TRISENOX to occur late in the fourth quarter.
POLYGLUTAMATE PRODUCTSThe Company plans on initiating phase II clinical trials with its lead drug candidate PG-TXL as single agent therapy, and/or in combination with conventional chemotherapy for first line treatment of lung and ovarian cancers, and for salvage therapy for colon and ovarian cancers in the first quarter. The Company expects to present results from its phase I trial at the ASCO meeting in May along with preliminary results from its phase II trials at analyst meetings in May and at the fall American Association of Cancer Research (AACR) clinical meeting in October. In addition to several peer reviewed publications, the Company plans to submit an Investigational New Drug (IND) application by year-end and subsequently begin clinical trials with its second drug candidate PG-Camptothecin (PG-CPT).
CT-2584The Company has completed enrollment in an 80 patient phase II trial of CT-2584 as salvage treatment for soft tissue sarcoma and plans to report the preliminary results of this study in the third quarter targeting a submission to the fall AACR meeting. In addition, the Company is initiating a trial of CT-2584 in combination with cisplatin to treat a variety of solid tumors. If successful in sensitizing tumors to platinum, the Company would plan on beginning phase II/III trials by the end of the year.
PANGENEXThe Company's majority owned functional genomics subsidiary has made progress toward demonstrating its potential to rapidly validate thousands of potential gene targets simultaneously, offering a significant potential advantage over the current approach of testing a single gene at a time. Small scale and large scale proof of principle is anticipated to be reached in the first and second quarters, respectively, leading to a peer reviewed publication in the third quarter. If successful, the Company is considering spinning out this subsidiary as an independent entity late this year. cti is committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.
Source: Cell Therapeutics Inc.
CMLSupport Home Page This site was last updated on Jan. 7, 2001 Copyright © 2000-2001 CMLSupport.com These contents may not be reproduced in whole or in part without the express written permission of the author, or she will beat you up and stuff. |